[Congressional Record Volume 170, Number 125 (Wednesday, July 31, 2024)]
[Senate]
[Page S5685]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

      By Mr. DURBIN (for himself, Mr. Blumenthal, Mr. Van Hollen, and 
        Mr. Brown):
  S. 4879. A bill to prioritize funding for an expanded and sustained 
national investment in biomedical research; to the Committee on 
Appropriations.
  Mr. DURBIN. Madam President, I ask unanimous consent that the text of 
the bill be printed in the Record.
  There being no objection, the text of the bill was ordered to be 
printed in the Record, as follows:

                                S. 4879

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``American Cures Act''.

     SEC. 2. APPROPRIATIONS FOR INNOVATION.

       (a) In General.--There are hereby authorized to be 
     appropriated, and appropriated, out of any monies in the 
     Treasury not otherwise appropriated, the following:
       (1) National institutes of health.--For the National 
     Institutes of Health at the Department of Health and Human 
     Services--
       (A) for fiscal year 2025, $52,468,000,000;
       (B) for fiscal year 2026, $56,665,000,000;
       (C) for fiscal year 2027, $61,198,000,000;
       (D) for fiscal year 2028, $66,094,000,000;
       (E) for fiscal year 2029, $71,382,000,000;
       (F) for fiscal year 2030, $77,093,000,000;
       (G) for fiscal year 2031, $83,260,000,000;
       (H) for fiscal year 2032, $89,921,000,000;
       (I) for fiscal year 2033, $97,115,000,000;
       (J) for fiscal year 2034, $104,884,000,000; and
       (K) for fiscal year 2035 and each fiscal year thereafter, 
     the amount appropriated under this paragraph for the previous 
     fiscal year, increased by the percentage increase (if any), 
     during the previous fiscal year, in the Consumer Price Index 
     for all urban consumers published by the Bureau of Labor 
     Statistics.
       (2) Centers for disease control and prevention.--For the 
     Centers for Disease Control and Prevention at the Department 
     of Health and Human Services--
       (A) for fiscal year 2025, $9,960,000,000;
       (B) for fiscal year 2026, $10,757,000,000;
       (C) for fiscal year 2027, $11,618,000,000;
       (D) for fiscal year 2028, $12,547,000,000;
       (E) for fiscal year 2029, $13,551,000,000;
       (F) for fiscal year 2030, $14,635,000,000;
       (G) for fiscal year 2031, $15,806,000,000;
       (H) for fiscal year 2032, $17,070,000,000;
       (I) for fiscal year 2033, $18,436,000,000;
       (J) for fiscal year 2034, $19,911,000,000; and
       (K) for fiscal year 2035 and each fiscal year thereafter, 
     the amount appropriated under this paragraph for the previous 
     fiscal year, increased by the percentage increase (if any), 
     during the previous fiscal year, in the Consumer Price Index 
     for all urban consumers published by the Bureau of Labor 
     Statistics.
       (3) Research, development, test, and evaluation program of 
     the department of defense health program.--For the research, 
     development, test, and evaluation program of the Department 
     of Defense health program--
       (A) for fiscal year 2025, $3,550,000,000;
       (B) for fiscal year 2026, $3,834,000,000;
       (C) for fiscal year 2027, $4,141,000,000;
       (D) for fiscal year 2028, $4,472,000,000;
       (E) for fiscal year 2029, $4,830,000,000;
       (F) for fiscal year 2030, $5,216,000,000;
       (G) for fiscal year 2031, $5,633,000,000;
       (H) for fiscal year 2032, $6,084,000,000;
       (I) for fiscal year 2033, $6,571,000,000;
       (J) for fiscal year 2034, $7,096,000,000; and
       (K) for fiscal year 2035 and each fiscal year thereafter, 
     the amount appropriated under this paragraph for the previous 
     fiscal year, increased by the percentage increase (if any), 
     during the previous fiscal year, in the Consumer Price Index 
     for all urban consumers published by the Bureau of Labor 
     Statistics.
       (4) Medical and prosthetics research program of the 
     department of veterans affairs.--For the medical and 
     prosthetics research program of the Department of Veterans 
     Affairs--
       (A) for fiscal year 2025, $1,018,000,000;
       (B) for fiscal year 2026, $1,099,000,000;
       (C) for fiscal year 2027, $1,187,000,000;
       (D) for fiscal year 2028, $1,282,000,000;
       (E) for fiscal year 2029, $1,385,000,000;
       (F) for fiscal year 2030, $1,496,000,000;
       (G) for fiscal year 2031, $1,616,000,000;
       (H) for fiscal year 2032, $1,745,000,000;
       (I) for fiscal year 2033, $1,885,000,000;
       (J) for fiscal year 2034, $2,035,000,000; and
       (K) for fiscal year 2035 and each fiscal year thereafter, 
     the amount appropriated under this paragraph for the previous 
     fiscal year, increased by the percentage increase (if any), 
     during the previous fiscal year, in the Consumer Price Index 
     for all urban consumers published by the Bureau of Labor 
     Statistics.
       (b) Availability.--Amounts appropriated under subsection 
     (a) shall remain available until expended.
       (c) Definitions.--In this section:
       (1) Centers for disease control and prevention.--The term 
     ``Centers for Disease Control and Prevention'' means the 
     appropriations accounts that support the various institutes, 
     offices, and centers that make up the Centers for Disease 
     Control and Prevention.
       (2) Research, development, test, and evaluation program of 
     the department of defense health program.--The term 
     ``research, development, test, and evaluation program of the 
     Department of Defense health program'' means the 
     appropriations accounts that support the various institutes, 
     offices, and centers that make up the research, development, 
     test, and evaluation program of the Department of Defense 
     health program.
       (3) Medical and prosthetics research program of the 
     department of veterans affairs.--The term ``medical and 
     prosthetics research program of the Department of Veterans 
     Affairs'' means the appropriations accounts that support the 
     various institutes, offices, and centers that make up the 
     medical and prosthetics research program of the Department of 
     Veterans Affairs.
       (4) National institutes of health.--The term ``National 
     Institutes of Health'' means the appropriations accounts that 
     support the various institutes, offices, and centers that 
     make up the National Institutes of Health.
       (d) Exemption of Certain Appropriations From 
     Sequestration.--
       (1) In general.--Section 255(g)(1)(A) of the Balanced 
     Budget and Emergency Deficit Control Act (2 U.S.C. 
     905(g)(1)(A)) is amended by inserting after ``Advances to the 
     Unemployment Trust Fund and Other Funds (16-0327-0-1-600).'' 
     the following:
       ``Appropriations under the American Cures Act.''.
       (2) Applicability.--The amendment made by this section 
     shall apply to any sequestration order issued under the 
     Balanced Budget and Emergency Deficit Control Act of 1985 (2 
     U.S.C. 900 et seq.) on or after the date of enactment of this 
     Act.
       (e) Budgetary Effects.--
       (1) Statutory paygo scorecards.--The budgetary effects of 
     this section shall not be entered on either PAYGO scorecard 
     maintained pursuant to section 4(d) of the Statutory Pay-As-
     You-Go Act of 2010 (2 U.S.C. 933(d)).
       (2) Senate paygo scorecards.--The budgetary effects of this 
     section shall not be entered on any PAYGO scorecard 
     maintained for purposes of section 4106 of H. Con. Res. 71 
     (115th Congress).
                                 ______